journal article·2024-06-10

H2S-Powered Nanomotors for Active Therapy of Tumors by Inducing Ferroptosis and Lactate-Pyruvate Axis Disorders

Weixin Wang, Renquan Fu, Rui Gao, Lei Luo, Zhongchao Wang, Yingli Xue, Jiahui Sun, Min Pan, Miaofang Hong, Lingyan Qiao, Weiwei Qiao, Qibing Mei, Jianming Wu, Yini Wang, Yali Zhong, Jin Liu, Fei Tong

Publisher page

Abstract

Disruption of the symbiosis of extra/intratumoral metabolism is a good strategy for treating tumors that shuttle resources from the tumor microenvironment. Here, we report a precision treatment strategy for enhancing pyruvic acid and intratumoral acidosis to destroy tumoral metabolic symbiosis to eliminate tumors; this approach is based on PEGylated gold and lactate oxidase-modified aminated dendritic mesoporous silica with lonidamine and ferrous sulfide loading (PEG-Au@DMSNs/FeS/LND@LOX). In the tumor microenvironment, LOX oxidizes lactic acid to produce pyruvate, which represses tumor cell proliferation by inhibiting histone gene expression and induces ferroptosis by partial histone monoubiquitination. In acidic tumor conditions, the nanoparticles release H 2 S gas and Fe 2+ ions, which can inhibit catalase activity to promote the Fenton reaction of Fe 2+, resulting in massive ·OH production and ferroptosis via Fe 3+ . More interestingly, the combination of H 2 S and LND (a monocarboxylic acid transporter inhibitor) can cause intracellular acidosis by lactate, and protons overaccumulate in cells. Multiple intracellular acidosis is caused by lactate-pyruvate axis disorders. Moreover, H 2 S provides motive power to intensify the shuttling of nanoparticles in the tumor region. The findings confirm that this nanomedicine system can enable precise antitumor effects by disrupting extra/intratumoral metabolic symbiosis and inducing ferroptosis and represents a promising active drug delivery system candidate for tumor treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Micro and Nano Robotics · Nanoplatforms for cancer theranostics · Genetic and Kidney Cyst Diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmacology, School of Pharmacy, Binzhou Medical University, Yantai, 264003, PR China

Key Laboratory of Tropical Biological Resources of Ministry of Education and One Health Institute, School of Pharmaceutical Sciences, Hainan University, Haikou 570228, China

Institute of Molecular Medicine (IMM), Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200240, China

Institute of Cardiovascular Disease, Shanxi Medical University, Taiyuan, 030001, PR China

Xi’an Medical University, Xi’an, 710000, PR China

Clinical Medical College, Binzhou Medical University, Yantai, 264003, PR China

Education Ministry Key Laboratory of Medical Electrophysiology, Sichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation, Luzhou; Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University, Luzhou, 646000, China

Southwest University of Science and Technology, 621000 Mianyang, China

School of Medicine, Zhejiang University, 310000 Hangzhou, China

Funding

Binzhou Medical University · Natural Science Foundation of Shandong Province

References (48)

Show source-provided references
1. 10.1016/j.bbcan.2019.18831410.1016/j.bbcan.2019.188314 ↗
2. 10.2174/187152061766617071315114910.2174/1871520617666170713151149 ↗
3. 10.1016/j.suronc.2016.03.00210.1016/j.suronc.2016.03.002 ↗
4. 10.1002/anie.20140609610.1002/anie.201406096 ↗
5. 10.1002/adma.20160325010.1002/adma.201603250 ↗
6. 10.1002/1521-3773(20020215)41:4<652::AID-ANIE652>3.0.CO;2-U10.1002/1521-3773(20020215)41:4<652::AID-ANIE652>3.0.CO;2-U ↗
7. 10.1021/acs.chemrev.5b0004710.1021/acs.chemrev.5b00047 ↗
8. 10.1039/C8NR00836A10.1039/C8NR00836A ↗
9. 10.1002/adma.20150258310.1002/adma.201502583 ↗
10. 10.1039/C6CS00885B10.1039/C6CS00885B ↗
11. 10.1021/nn302899710.1021/nn3028997 ↗
12. 10.1021/jacs.8b0576210.1021/jacs.8b05762 ↗
13. 10.1039/C4NR03124E10.1039/C4NR03124E ↗
14. 10.1038/nchem.128110.1038/nchem.1281 ↗
15. 10.1002/anie.20150418610.1002/anie.201504186 ↗
16. 10.1039/C6CC09169E10.1039/C6CC09169E ↗
17. 10.1002/adfm.20170508610.1002/adfm.201705086 ↗
18. 10.1021/acsnano.8b0376010.1021/acsnano.8b03760 ↗
19. 10.1021/acsnano.6b0479510.1021/acsnano.6b04795 ↗
20. 10.1038/s41467-017-00309-w10.1038/s41467-017-00309-w ↗
21. 10.1021/nn507097k10.1021/nn507097k ↗
22. 10.1126/sciadv.aat438810.1126/sciadv.aat4388 ↗
23. 10.1002/adfm.20170610010.1002/adfm.201706100 ↗
24. 10.1126/scirobotics.aam643110.1126/scirobotics.aam6431 ↗
25. 10.1126/scirobotics.aaz951910.1126/scirobotics.aaz9519 ↗
26. 10.1002/adma.20200051210.1002/adma.202000512 ↗
27. 10.1038/s41467-019-08670-810.1038/s41467-019-08670-8 ↗
28. 10.1002/anie.20201368910.1002/anie.202013689 ↗
29. 10.15252/embr.20184756310.15252/embr.201847563 ↗
30. 10.1002/anie.20210430410.1002/anie.202104304 ↗
31. 10.1021/acsami.0c0059610.1021/acsami.0c00596 ↗
32. 10.1016/j.bioactmat.2021.04.00410.1016/j.bioactmat.2021.04.004 ↗
33. 10.3892/ol.2017.599410.3892/ol.2017.5994 ↗
34. 10.1016/j.cca.2019.01.01110.1016/j.cca.2019.01.011 ↗
35. 10.1038/s41422-020-0383-910.1038/s41422-020-0383-9 ↗
36. 10.1186/s13045-020-00985-010.1186/s13045-020-00985-0 ↗
37. 10.1016/j.mri.2011.07.00110.1016/j.mri.2011.07.001 ↗
38. 10.1093/nar/gkz86410.1093/nar/gkz864 ↗
39. 10.1155/2021/821804310.1155/2021/8218043 ↗
40. 10.1002/ijc.2480010.1002/ijc.24800 ↗
41. 10.1038/nature2543210.1038/nature25432 ↗
42. 10.1038/s41467-020-20154-810.1038/s41467-020-20154-8 ↗
43. 10.1158/1535-7163.MCT-12-070010.1158/1535-7163.MCT-12-0700 ↗
44. 10.18632/oncotarget.1380810.18632/oncotarget.13808 ↗
45. 10.1002/hep.2869010.1002/hep.28690 ↗
46. 10.18632/oncotarget.797210.18632/oncotarget.7972 ↗
47. 10.4161/cbt.10.2.1258110.4161/cbt.10.2.12581 ↗
48. 10.1093/neuonc/noab11410.1093/neuonc/noab114 ↗